menu
    • menu
    [{"orgOrder":0,"company":"National Center of Neurology and Psychiatry, Japan","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Phase I","graph3":"National Center of Neurology and Psychiatry, Japan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Center of Neurology and Psychiatry, Japan \/ Nippon Shinyaku","highestDevelopmentStatusID":"6","companyTruncated":"National Center of Neurology and Psychiatry, Japan \/ Nippon Shinyaku"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Nippon Shinyaku | Cooperative International Neuromuscular Research Group | Therapeutic Research in Neuromuscular Disorders Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2016","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Nippon Shinyaku | Cooperative International Neuromuscular Research Group | Therapeutic Research in Neuromuscular Disorders Solutions","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Nippon Shinyaku | Cooperative International Neuromuscular Research Group | Therapeutic Research in Neuromuscular Disorders Solutions"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Nippon Shinyaku | Cooperative International Neuromuscular Research Group | Therapeutic Research in Neuromuscular Disorders Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Nippon Shinyaku | Cooperative International Neuromuscular Research Group | Therapeutic Research in Neuromuscular Disorders Solutions","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Nippon Shinyaku | Cooperative International Neuromuscular Research Group | Therapeutic Research in Neuromuscular Disorders Solutions"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nippon Shinyaku \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nippon Shinyaku \/ Undisclosed"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Nippon Shinyaku"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Nippon Shinyaku"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Option Care Health","sponsor":"NS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Option Care Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Option Care Health \/ NS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Option Care Health \/ NS Pharma"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Viltolarsen

    Menu

    Viltolarsen

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NS Pharma Shares Preliminary Results Of Viltolarsen Phase 3 Trial

                            Details : Viltepso (viltolarsen), an antisense oligonucleotide, is being investigated in ambulatory boys with Duchenne muscular dystrophy.

                            Product Name : Viltepso

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 27, 2024

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NS Pharma Reports on Results of VILTEPSO® (viltolarsen) Injection After Four Years of Treatment in Open-Label...

                            Details : VILTEPSO® (viltolarsen) injection,is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

                            Product Name : Viltepso

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 24, 2022

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VILTEPSO® (viltolarsen) Injection Four-Year Clinical Trial Data to be Presented at the World Muscle Society 2...

                            Details : VILTEPSO (viltolarsen) is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

                            Product Name : Viltepso

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 04, 2022

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VILTEPSO® (viltolarsen) Injection: Long-Term Efficacy and Safety Data Published in the Journal of Neuromuscul...

                            Details : VILTEPSO (Viltolarsen) is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

                            Product Name : Viltepso

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 31, 2022

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the Wor...

                            Details : Viltepso (viltolarsen) is an antisense oligonucleotide used to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

                            Product Name : Viltepso

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            September 17, 2021

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Nippon Shinyaku

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With D...

                            Details : Viltolarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 09, 2021

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Nippon Shinyaku

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VILTEPSO® (Viltolarsen) Injection: Long-Term Efficacy and Safety Data Presented at the PPMD 2021 Virtual Annu...

                            Details : In addition to this Phase 2 open-label extension study, NS Pharma continues to investigate the efficacy and safety of VILTEPSO in the confirmatory Phase 3 RACER53 trial.

                            Product Name : Viltepso

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 01, 2021

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VILTEPSO (viltolarsen) Injection Long-Term Clinical Trial Data to be Presented at the PPMD 2021 Virtual Annual...

                            Details : Phase 2 open-label extension study, NS Pharma continues to investigate the efficacy and safety of VILTEPSO in the confirmatory Phase 3 RACER53 trial. This study was initiated in October 2019 and is currently enrolling patients.

                            Product Name : Viltepso

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 12, 2021

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Nippon Shinyaku

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

                            Details : Viltolarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 24, 2021

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Nippon Shinyaku

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NS Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

                            Details : Viltolarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 29, 2020

                            Lead Product(s) : Viltolarsen

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth